Form 4: Alnylam Pharmaceuticals EVP, CFO Jeffrey V. Poulton Reports Stock Transactions

Jeffrey V. Poulton, EVP and CFO of Alnylam Pharmaceuticals, reports acquisition and disposal of company stock, including shares from vested performance-based stock units and sales to cover tax obligations.

Summary

• On February 13, 2025, Jeffrey V. Poulton, EVP and CFO of Alnylam Pharmaceuticals, acquired 3,109 shares of common stock upon vesting of a performance-based stock unit (PSU).
• The PSU vested because Alnylam publicly reported achievement of non-GAAP operating income profitability for a 12-month calendar year, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors.
• Between February 14, 2025, Poulton sold a total of 724 shares of common stock at prices ranging from $252.50 to $264.87 per share.
• These sales were automatically executed by the company to cover minimum statutory tax withholding obligations due upon the vesting and settlement of restricted stock units.
• Poulton also holds 57 shares indirectly through a managed account.
• Following these transactions, Poulton directly owns 32,786 shares of Alnylam common stock and indirectly owns 57 shares through a managed account.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs suggests the company is meeting its performance goals, but the subsequent stock sales introduce a slightly negative element, although they are likely for tax purposes.

Positives

• The vesting of the performance-based stock unit indicates that Alnylam Pharmaceuticals achieved a key performance milestone: non-GAAP operating income profitability for a 12-month calendar year.
• Poulton's continued direct ownership of 32,786 shares demonstrates a continued investment in the company's future.

Negatives

• The sale of 724 shares, even if for tax obligations, could be perceived negatively by some investors, although it is a common practice.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Comparing Poulton's transactions to those of executives at similar-sized biotech companies like Ionis Pharmaceuticals or Sarepta Therapeutics could provide context.
• Analyzing the ratio of stock sales to total holdings among peer group CFOs could offer insights into Poulton's actions.
• Benchmarking Alnylam's non-GAAP operating income profitability against industry averages would help assess the significance of this achievement.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign of company performance.
• Employees may be motivated by the achievement of profitability targets and the resulting vesting of stock awards.
• The transactions have a minimal direct impact on customers, suppliers, and creditors.

Key Dates

Keywords

Alnylam Pharmaceuticals, Jeffrey V. Poulton, stock transactions, Form 4, insider trading, performance-based stock unit, non-GAAP operating income, tax withholding, ALNY